Abstract
Hepatic steatosis (HS) is a recognised entity in people with CF (pwCF), yet guidance on its treatment is lacking. HS prevalence may increase as more pwCF become overweight and with increased CF longevity. Similarities to non-alcoholic fatty liver disease (NAFLD) raises concerns around progression to liver fibrosis. It’s unclear if pwCF are receiving dietary advice to support HS management and, if so, what this advice entails.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
